Dew, your post concerning the reasonable valuation for Genaera is by far the clearest and most valuable one I have ever read. Thank you. You have expressed without ANY hyperbole the underlying value of this company, and I would bet your analysis rivals that of the three Analysts houses that have issued recommendations. Kudos to you and Bravo!
Excellent informative post! Thank you. The folks on the Yahoo board should be reading and researching the information you and others like DrBio provide instead of creating such a mess on the Yahoo board.
Thanks for sharing all your knowledge with us less informed people. You value Genr at $11.50. Imcl with a float about 50% larger in the very competitive and getting moreso cancer market is at approx. $40 these days. Does Imcl seem high at this price, does Genr have a chance to reach the price level of Imcl?
Dew, DrBio, or anyone, Are there any theories on why GENR's vegf would (should, may) work better for wet AMD intravenously than competing and approved drugs injected directly? I'm curious as to why the genr version would be any different or head to head same administration should have any notable advantage particularly over other anti-vegf drugs.
2 trading days left for MEDI to meet their guidance of IL-9 IND in 2003.
Market Data 
Markets 
AI
